LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


International Biotechnology Trust Plc

18.00 (2.74%)
Share Name Share Symbol Market Type Share ISIN Share Description
International Biotechnology Trust Plc LSE:IBT London Ordinary Share GB0004559349 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  18.00 2.74% 676.00 56,625 16:35:08
Bid Price Offer Price High Price Low Price Open Price
674.00 676.00 674.00 664.00 664.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Trusts -13.58 -22.47 -54.30 - 275.57
Last Trade Time Trade Type Trade Size Trade Price Currency
16:39:42 AT 309 676.00 GBX

International Biotechnol... (IBT) Latest News (2)

International Biotechnol... (IBT) Discussions and Chat

International Biotechnol... Forums and Chat

Date Time Title Posts
25/4/202314:24International Biotechnolgy Trust377
29/4/201910:54International Boitechnology Trust148
21/10/200104:31"Biotech names selling on air"2
28/12/200012:08Soros buys Int.Biotech stake5
17/7/200018:11Int Biotech1

Add a New Thread

International Biotechnol... (IBT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

International Biotechnol... (IBT) Top Chat Posts

Top Posts
Posted at 25/4/2023 14:24 by davidosh
IBT are on the show this afternoon and it is free to join and also receive the recording


Posted at 13/3/2023 12:58 by speedsgh
As per c34's post above...

Portfolio Update as at 13 March 2023 - HTTPS://

The Company notes that Pfizer Inc (NYSE: PFE) has announced that it entered a definitive agreement to acquire IBT's portfolio company Seagen Inc. (Nasdaq: SGEN) for $229 per share which represents a 32.7% premium to the closing price of Seagen Inc on 10 March 2023 of $172.61.

Prior to the announcement on 13 March 2023, IBT owned 200,200 shares in Seagen, which is the trust's largest position representing 10.2% of IBT's Net Asset Value, as at the close on Friday 10 March 2023.

Posted at 16/12/2022 10:25 by speedsgh
International Biotech shares rally on strong dealflow - HTTPS://

Shares in International Biotechnology Trust (IBT) have rallied more than 3% after a flurry of good news this week, including Amgen’s acquisition of its largest position Horizon Therapeutics.

The US pharma giant agreed to acquire the biotech stock, which focuses on developing drugs for rare autoimmune diseases, for $116.5 per share on Monday, a nearly 50% premium to the share price when talks began last month.

Given its 13.5% weighting in International Biotechnology’s portfolio, the takeover will add 2.7% to net asset value (NAV), broker Numis estimated.

The £283m trust also announced a material revaluation to one of its unquoted investments managed by parent company SV Health Managers, which will lead to a £2.5m, or 0.8%, uplift to NAV.

It is unclear which company it refers to, but on Tuesday SV Health Managers issued a press release stating that Japanese pharma company Takeda had agreed to acquire Nimbus Therapeutics’ allosteric TYK2 inhibitor, which addresses multiple immune-mediated diseases. Nimbus will receive $4bn upfront cash and up to $2bn in commercial milestone payments, it said.

Following the investment company’s annual results in November, manager Ailsa Craig told Citywire that the US Inflation Reduction Act, which was passed in August this year, will likely increase the levels of mergers and acquisitions.

‘The positive for our sector and our companies is: will that increase the demand for M&A? I think maybe it could. It looks like the biotech market sector shrugged it off but it’s probably all these market forces balancing each other out,’ she said.

Since close on Friday, IBT’s shares have rallied 3.3% to 713p.

Over five years, shareholders have enjoyed a 42.2% total return, ahead of the 25.9% average in the Biotechnology & Healthcare peer group tracked by the Association of Investment Companies.

Posted at 14/12/2022 07:30 by speedsgh
Portfolio Update as at 13 December 2022 - HTTPS://

The Company notes that there has been a material adjustment to the valuation of an investment from the unquoted portfolio managed by SV Health Managers LLP in which the Company is invested.

The net asset value of the Company will therefore increase by £2.5m ($3.1m) which corresponds to 6p per share uplift and will be incorporated into today's unaudited net asset value (calculated on the AIC basis).

Posted at 07/12/2022 16:13 by speedsgh
Dividend Declaration - HTTPS://

So 28.00p dividend for the current FY...

interim (Jan 23) - 14.00p
TOTAL FY 2021/22 - 31.40p
final (Aug 22) - 15.70p
interim (Jan 22) - 15.70p
TOTAL FY 2020/21 - 28.40p
final (Aug 21) - 14.20p
interim (Jan 21) - 14.20p
TOTAL FY 2019/20 - 24.80p
final (Aug 20) - 12.40p
interim (Jan 20) - 12.40p
TOTAL FY 2018/19 - 28.00p
final (Aug 19) - 14.00p
interim (Jan 19) - 14.00p
TOTAL FY 2017/18 - 27.00p
final (Aug 18) - 13.50p
interim (Jan 18) - 13.50p
TOTAL FY 2016/17 - 23.00p
final (Aug 17) - 11.50p
interim (Jan 17) - 11.50p

Posted at 27/7/2022 10:39 by speedsgh
Dividend Declaration - HTTPS://

At the Annual General Meeting held on 8 December 2021, Shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), through two equal semi-annual distributions. In accordance with this policy, the first Interim Dividend for the period ending 31 August 2022 was paid in January 2022.

The Directors have today declared the second Interim Dividend for the period ending 31 August 2022 of 15.7p per Ordinary Share.

The second Interim Dividend will be payable on Friday, 26 August 2022 to holders of Ordinary Shares on the Register at the close of business on Friday, 5 August 2022 (ex-dividend Shares on the Register at Thursday, 4 August 2022).

Posted at 15/5/2022 22:23 by melloteam
Mello2022, the popular three-day Investor event takes place on 24TH-26TH MAY at the Clayton Hotel & Conference Centre, Chiswick, W4. The breakdown of the three days is as follows:

Tuesday 24th May, 9am - 6pm - Mello Investment Trusts and Funds (WE ARE GIVING AWAY 20 FREE TICKETS TO THE TRUST AND FUNDS EVENT - THE FREE CODE IS FIRST20TF)

Wednesday 25th & Thursday 26th May, 9am - 6pm - Smaller Growth and Mid-Cap Companies (Tickets for 1 day are £115 and tickets for 2 days are £189. To get 50% off, use code MMTADVFN50).

Just to let shareholders and prospective investors know that IBT will be among the Trusts and Funds attending. There will also be keynote speakers such as Lord John Lee, Andy Brough, Rosemary Banyard, Clarke Carlisle and Gervais Williams.

For more information, please visit the event webpage: Https://

Posted at 10/5/2022 19:23 by speedsgh

$IBT 4.1% of the latest NAV for #IntlBiotechTrust is in Biohaven $BHVN which has just agreed an $11.6bn cash bid from Pfizer $PFE. This adds ca.$3.0m/£2.4m to valuation. Uplift on last night's NAV is ca.3%. HTTPS://


From IBT website...

Top 10 Quoted Investments (as at 28/2/22) - HTTPS://

5.1% of NAV - Horizon Therapeutics
5.0% of NAV - Neurocrine Biosciences
5.0% of NAV - Incyte
4.5% of NAV - Ultragenyx
4.5% of NAV - Illumina
4.3% of NAV - Amgen
4.1% of NAV - Biohaven Pharmaceuticals
4.1% of NAV - Mirati Therapeutics
4.1% of NAV - PTC Therapeutics
3.0% of NAV - Argenx

Posted at 04/5/2022 08:11 by speedsgh
Half Year Report - HTTPS://

In the first six months of the year the Fund Manager produced strong relative performance, albeit against a weak biotechnology market. For the six months ended 28 February 2022, the NAV per share returned -13.1%. By comparison, the NBI returned -23.0%. Over the same period, the ordinary share price of the Company returned -9.4%. Although negative returns are always disappointing, it is encouraging that IBT has substantially outperformed its comparator index over this difficult period for biotechnology shares. The Company's share price continues to outperform the NBI by 1.7% and 8.7% respectively over a 3 and 5-year period, with the 1-year period underperforming by -0.6%. All figures are on a sterling adjusted total return basis, with dividends reinvested...

The Fund Manager and Directors will continue to actively monitor the global economic and geopolitical situation and any potential impact on the biotechnology sector's prospects, financial condition and outlook.

Although the market has been shaken by the horrors of the war in Eastern Europe and its concomitant economic impact, the fundamentals of the biotech industry remain intact. The companies that the Company is invested in remain strong with innovation still continuing apace and demand for new therapies rising, as the elderly population grows and developing markets gain better access to medicines. The Company has not invested in any Russian companies.

From a broader economic perspective, the lessening impact of the pandemic should be positive for economic growth but brings with it the risk of inflation. The past months have seen volatility in the market which is likely to continue but the Directors are encouraged that valuations in the biotech sector are currently at historically low levels and share the Fund Manager's optimism for a rebound. Catalysts could include a return of M&A to the sector fuelled by a combination of cash rich big pharmaceutical companies looking to replenish their pipelines and smaller biotech companies trading at attractive valuations. The Fund Manager's active investment strategy will ensure that the Company is well placed to identify possible beneficiaries of a rebound. As a Board we have confidence that the Fund Manager will continue to seek to deliver market beating returns.

Posted at 01/11/2021 15:07 by speedsgh
Annual Financial Report - HTTPS://

The twelve month period to the end of August 2021 has almost been as dramatic as the previous twelve months, with lockdowns giving way to double vaccinations as the prime means of controlling COVID-19. Over that period the Company's NAV per share and share price have returned 9.8% and 3.8% respectively whilst the Nasdaq Biotechnology Index (NBI) and the FTSE All-Share index returned 22.8% and 26.9% respectively. All figures are on a total return basis*, including costs and assuming dividends reinvested, and are sterling-adjusted.

Whilst this is a disappointing outcome, as discussed below there has been a short-term factor impacting relative performance and the Board remains confident that the Investment Managers will outperform in the future. Longer term performance remains good in what has historically been a volatile sector with five year annualised returns of 10.3% and 12.3% on the NAV and share price respectively...

... The main reason for the 2020/21 underperformance was that the Company was prevented from investing in vaccine producing companies due to an agreement made between the Manager, SV Health Managers LLP and the UK Government when Kate Bingham was working as the Chair of the Vaccine Taskforce for the United Kingdom. This agreement was entered into to ensure that neither SV nor its clients were seen to benefit from Kate Bingham's privileged access to information contained in the government contracts with the named vaccine suppliers.

These COVID-19-vaccine stocks have performed extraordinarily well and have outperformed hugely the average of the other biotechnology stocks contained within the NBI. The overall performance of the Company's NAV on a like-for-like basis would have outperformed the NBI if we measured both returns excluding the COVID-19-vaccine producing companies. Further details on this can be found in the Fund Manager's Review.

The Board is very proud of the outstanding contribution of Kate Bingham in helping to secure a leading supply of vaccines for the UK...

International Biotechnol... share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230605 16:59:59